ZYUS Life Sciences Corporation Announces Closing of Fifth Tranche of Secured Loan Financing

About this update from Zyus Life Sciences Corporation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ SASKATOON, SK, July 2, 2026 /CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, is pleased to announce that its wholly-owned subsidiary, ZYUS Life Sciences Inc. ("ZYUS Inc."), has closed a fifth tranche (the "Fifth Tranche") of a secured loan financing (the "Secured Loan") on July 2, 2026 with certain lenders (the "Lenders"), including certain insiders of the Company, for gross proceeds of CAD$150,000. The closing of the Fifth Tranche brings the total amount of the Secured Loan to CAD$845,000. ZYUS Inc. expects to close additional tranches under the Secured Loan. The aggregate size of the Secured Loan offering is up to CAD$2,000,000. Subject to receipt of approval from the TSX Venture Exchange (the "Exchange"), the Secured Loan will be secured by a security interest granted under the terms of a general security agreement (subject to an exception in respect of certain assets). The Secured Loan bears interest at a rate of 12% per annum, payable on maturity, is pre-payable by ZYUS Inc. at any time without penalty or premium, and will mature six months from the effective date of the loan. As the Lenders that participated in the Fifth Tranche of the Secured Loan are members of the Company's Board of Directors, such participation constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company has relied on the exemption from the valuation requirement pursuant to section 5.5(b) (Issuer Not Listed on Specified Markets) of MI 61-101 and from the minority shareholder approval requirement prescribed by section 5.7(1)(a) (Fair Market Value Not More Than 25 Percent of Market Capitalization) of MI 61-101. The Company did not file a material change report more than 21 days before issuance of the Secured Loan because the details of the Secured Loan were not settled until recently. The Company intends to use the net proceeds of the Fifth Tranche for general working capital purposes. There is no undisclosed material information by the Company, and all independent directors have approved the Secured Loan desc...

View stock analysis, news, and events for Zyus Life Sciences Corporation